AbbVie

Immunology

ABBV · NYSE · United States

Share price · ABBV

$286.01+27.09 (+10.46%) 3M

close as of 2026-11-18 · 24h delayed · vol 4.8M (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ABBV's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 2 Nov 2026-2.1%
  2. 22 Jun 2026+6.2%
  3. 29 Apr 2026+3.1%
  4. 18 Mar 2026-5.2%
  5. 12 Feb 2026+3.0%
  6. 4 Feb 2026-3.8%
  7. 8 Jan 2026-4.0%
  8. 7 Jan 2026+4.2%
  9. 5 Jan 2026-4.0%
  10. 24 Nov 2025-2.9%

Share of unusual movement by asset

For each asset, the share of ABBV's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
upadacitinib (Rinvoq)
events and moves
168%
Zumilokibart
events and moves
83%
onabotulinumtoxinA (Botox)
events and moves
122%
Surabgene lomparvovec
events and moves
91%
Epcoritamab
events and moves
121%
risankizumab (Skyrizi)
events and moves
7shown from 8 days
Tavapadon (Juvmo)
events and moves
6shown from 8 days
Etentamig
events and moves
4shown from 8 days
Atogepant (Qulipta) (Qulipta)
events and moves
3shown from 8 days
ABBV-295
events and moves
2shown from 8 days
Cariprazine (Vraylar) (Vraylar)
events and moves
2shown from 8 days
Bretisilocin
events and moves
2shown from 8 days
foslevodopa/foscarbidopa (Vyalev)
events and moves
2shown from 8 days
Pivekimab Sunirine (Decnupaz)
events and moves
2shown from 8 days
ABBV-2001
events and moves
2shown from 8 days
Telisotuzumab Vedotin
events and moves
2shown from 8 days
Telisotuzumab Adizutecan
events and moves
2shown from 8 days
RC148
events and moves
2shown from 8 days
adalimumab (Humira)
events and moves
1shown from 8 days
lutikizumab
events and moves
1shown from 8 days
Fosigotifator
events and moves
1shown from 8 days
APG808
events and moves
1shown from 8 days
Venetoclax
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—6%
Other company news (earnings, financing, releases naming no asset)—36%
Sessions with no dated event—43%

Assets

(78 total)
78Total Assets
22Approved
6Phase 3 / Filed
50Phase 1–2 / Early
46Diseases
Quick filter:
Showing 78 of 78 assets
Target & Modality
adalimumab(Humira)
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis
Ulcerative Colitis, Crohn's Disease
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
SchizophreniaBipolar Disorder
Approved
CGRP receptorSmall molecule
Migraine
Approved
Dopamine D3/D2 receptor (partial agonist)Small molecule
Major Depressive DisorderSchizophreniaBipolar DisorderBipolar Depression
Approved
GABAergic neurotransmissionSmall molecule
EpilepsyMigraineBipolar Disorder
Focal Onset Seizures, Absence Seizures
Approved
GABAergic neurotransmissionSmall molecule
EpilepsyMigraineBipolar Disorder
Focal Onset Seizures, Absence Seizures
Approved
SLAMF7 (CS1/CD319)Monoclonal antibody
Multiple Myeloma
Approved
CD20 x CD3Multispecific antibody
Diffuse Large B-Cell LymphomaFollicular LymphomaNon-Hodgkin Lymphoma
Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma
Approved
dopamine precursorSmall molecule
Parkinson's Disease
Approved
BTKSmall molecule
Diffuse Large B-Cell LymphomaGraft-versus-Host DiseaseMantle Cell LymphomaChronic Lymphocytic Leukemia
Chronic Graft-versus-Host Disease
Approved
dopamine precursorSmall molecule
Parkinson's Disease
linaclotide(Linzess)
Approved
Guanylate cyclase-C (GC-C)Peptide
Irritable Bowel Syndrome
Irritable Bowel Syndrome with Constipation
Approved
AminosalicylateSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis
Approved
—Antibody–drug conjugate
Ovarian Cancer
Approved
Acetylcholine Release Inhibitor · acetylcholine releaseBiologic (subtype unspecified)
Migraine

Discontinued programmes (6)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(130 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (12)
November 2026 (7)
BudigalimabPhase 2Hepatocellular Carcinoma
Est. primary completion 2026-11 · NCT05822752 · CT.gov ↗
What to watch
ZumilokibartPhase 2Atopic Dermatitis
Est. primary completion 2026-11 · NCT06395948 · CT.gov ↗
What to watch
Mirvetuximab soravtansine · ElaherePhase 2High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Est. primary completion 2026-11 · NCT05456685 · CT.gov ↗
What to watch
VenetoclaxPhase 2Chronic Lymphocytic Leukemia (CLL)
Est. primary completion 2026-11 · NCT04895436 · CT.gov ↗
What to watch
ABBV-932Phase 2Generalized Anxiety Disorder (GAD)
Est. primary completion 2026-11 · NCT06846320 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3Atopic Dermatitis
Est. primary completion 2026-11 · NCT06389136 · CT.gov ↗
What to watch
ElotuzumabPhase 1/2Multiple Myeloma
Est. primary completion 2026-11-30 · NCT03989414 · CT.gov ↗
What to watch
December 2026 (5)
Telisotuzumab AdizutecanPhase 2Unresectable Metastatic Colorectal Cancer
Est. primary completion 2026-12 · NCT06107413 · CT.gov ↗
What to watch
Surabgene lomparvovecPhase 2/3AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration …
Est. primary completion 2026-12 · NCT04704921 · CT.gov ↗
What to watch
lutikizumabPhase 3Hidradenitis Suppurativa
Est. primary completion 2026-12 · NCT06468228 · CT.gov ↗
What to watch
Cariprazine (Vraylar)Phase 3Schizophrenia
Est. primary completion 2026-12-15 · NCT03817502 · CT.gov ↗
What to watch
IbrutinibPhase 3Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma …
Est. primary completion 2026-12-31 · NCT01804686 · CT.gov ↗
What to watch
2027 (39)
January 2027 (2)
BudigalimabPhase 2/3Hepatocellular Carcinoma
Est. primary completion 2027-01 · NCT06109272 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3Atopic Dermatitis
Est. primary completion 2027-01 · NCT06701331 · CT.gov ↗
What to watch
February 2027 (4)
Venetoclax + Pivekimab Sunirine · DecnupazPhase 1/2Acute Myeloid Leukemia
Est. primary completion 2027-02 · NCT04086264 · CT.gov ↗
What to watch
Mirvetuximab soravtansine · ElaherePhase 2Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
Est. primary completion 2027-02 · NCT06365853 · CT.gov ↗
What to watch
lutikizumabPhase 2Hidradenitis Suppurativa, Atopic Dermatitis
Est. primary completion 2027-02 · NCT06524635 · CT.gov ↗
What to watch
lutikizumab + RavagalimabPhase 2Rheumatoid Arthritis
Est. primary completion 2027-02 · NCT06972446 · CT.gov ↗
What to watch
March 2027 (6)
BudigalimabPhase 2Urothelial Carcinoma
Est. primary completion 2027-03 · NCT06632951 · CT.gov ↗
What to watch
EpcoritamabPhase 2Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma
Est. primary completion 2027-03 · NCT05451810 · CT.gov ↗
What to watch
ABBV-932Phase 2Bipolar I or II Disorder
Est. primary completion 2027-03 · NCT07220460 · CT.gov ↗
What to watch
risankizumab · SkyriziPhase 3Crohn's Disease
Est. primary completion 2027-03 · NCT06063967 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3Systemic Lupus Erythematosus
Est. primary completion 2027-03 · NCT05843643 · CT.gov ↗
What to watch
Cariprazine (Vraylar)Phase 3Depression, Bipolar I Disorder
Est. primary completion 2027-03 · NCT04777357 · CT.gov ↗
What to watch
April 2027 (1)
Mirvetuximab soravtansine · ElaherePhase 3Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Est. primary completion 2027-04 · NCT05445778 · CT.gov ↗
What to watch
May 2027 (3)
lutikizumabPhase 2Atopic Dermatitis
Est. primary completion 2027-05 · NCT06718101 · CT.gov ↗
What to watch
Ubrogepant (Ubrelvy)Phase 3Migraine
Est. primary completion 2027-05 · NCT05125302 · CT.gov ↗
What to watch
RC148Phase 2/3Colorectal (Colon or Rectal) Cancer
Est. primary completion 2027-05-12 · NCT07462143 · CT.gov ↗
What to watch
June 2027 (2)
VenetoclaxPhase 2Multiple Myeloma
Est. primary completion 2027-06 · NCT02899052 · CT.gov ↗
What to watch
EpcoritamabPhase 3Diffuse Large B-Cell Lymphoma
Est. primary completion 2027-06 · NCT05578976 · CT.gov ↗
What to watch
July 2027 (2)
upadacitinib · RinvoqPhase 3Ulcerative Colitis (UC)
Est. primary completion 2027-07 · NCT03006068 · CT.gov ↗
What to watch
VenetoclaxPhase 3Myelodysplastic Syndrome (MDS)
Est. primary completion 2027-07 · NCT04401748 · CT.gov ↗
What to watch
August 2027 (3)
Telisotuzumab AdizutecanPhase 2Metastatic Colorectal Cancer
Est. primary completion 2027-08 · NCT06614192 · CT.gov ↗
What to watch
risankizumab · SkyriziPhase 3Ulcerative Colitis
Est. primary completion 2027-08 · NCT06880744 · CT.gov ↗
What to watch
VenetoclaxPhase 3Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer
Est. primary completion 2027-08 · NCT03844048 · CT.gov ↗
What to watch
September 2027 (5)
EpcoritamabPhase 1/2Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma …
Est. primary completion 2027-09 · NCT04542824 · CT.gov ↗
What to watch
adalimumab · Humira + lutikizumabPhase 2Ulcerative Colitis
Est. primary completion 2027-09 · NCT06257875 · CT.gov ↗
What to watch
IcalcaprantPhase 2Major Depressive Disorder
Est. primary completion 2027-09 · NCT07276997 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3Crohn's Disease
Est. primary completion 2027-09 · NCT03345823 · CT.gov ↗
What to watch
EpcoritamabPhase 1/2Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Est. primary completion 2027-09-30 · NCT04663347 · CT.gov ↗
What to watch
October 2027 (1)
EpcoritamabPhase 1/2B-Cell Non-Hodgkin Lymphoma
Est. primary completion 2027-10 · NCT05201248 · CT.gov ↗
What to watch
November 2027 (4)
Budigalimab + Telisotuzumab AdizutecanPhase 1/2Non Small Cell Lung Carcinoma, c-MET
Est. primary completion 2027-11 · NCT06772623 · CT.gov ↗
What to watch
FosigotifatorPhase 1/2Vanishing White Matter Disease
Est. primary completion 2027-11 · NCT05757141 · CT.gov ↗
What to watch
IcalcaprantPhase 2Bipolar I Disorder, Bipolar II Disorder
Est. primary completion 2027-11 · NCT06696755 · CT.gov ↗
What to watch
Ubrogepant (Ubrelvy)Phase 3Migraine
Est. primary completion 2027-11 · NCT06417775 · CT.gov ↗
What to watch
December 2027 (6)
EpcoritamabPhase 1/2Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome …
Est. primary completion 2027-12 · NCT04623541 · CT.gov ↗
What to watch
lutikizumabPhase 2Hidradenitis Suppurativa
Est. primary completion 2027-12 · NCT05139602 · CT.gov ↗
What to watch
RC148Phase 2Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by H …
Est. primary completion 2027-12 · NCT07874282 · CT.gov ↗
What to watch
Elotuzumab + EtentamigPhase 3Multiple Myeloma
Est. primary completion 2027-12 · NCT06158841 · CT.gov ↗
What to watch
IbrutinibPhase 2Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
Est. primary completion 2027-12-15 · NCT05963074 · CT.gov ↗
What to watch
RC148Phase 3Non-Small Cell Lung Cancer
Est. primary completion 2027-12-31 · NCT07416474 · CT.gov ↗
What to watch
2028 (25)
January 2028 (2)
IMGN-151Phase 2Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
Est. primary completion 2028-01 · NCT07024784 · CT.gov ↗
What to watch
Ubrogepant (Ubrelvy)Phase 3Migraine
Est. primary completion 2028-01 · NCT05127954 · CT.gov ↗
What to watch
February 2028 (4)
EtentamigPhase 1/2Immunoglobulin Light Chain (AL) Amyloidosis
Est. primary completion 2028-02 · NCT06158854 · CT.gov ↗
What to watch
EmraclidinePhase 2Schizophrenia
Est. primary completion 2028-02 · NCT07145918 · CT.gov ↗
What to watch
Telisotuzumab VedotinPhase 2Non-Small Cell Lung Cancer, c-MET
Est. primary completion 2028-02 · NCT06568939 · CT.gov ↗
What to watch
risankizumab · SkyriziPhase 3Crohn's Disease (CD)
Est. primary completion 2028-02 · NCT04524611 · CT.gov ↗
What to watch
March 2028 (6)
ABBV-295Phase 2Obesity, Overweight
Est. primary completion 2028-03 · NCT07752979 · CT.gov ↗
What to watch
Telisotuzumab AdizutecanPhase 2Metastatic Colorectal Cancer
Est. primary completion 2028-03 · NCT06820463 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3Vitiligo
Est. primary completion 2028-03 · NCT06118411 · CT.gov ↗
What to watch
EpcoritamabPhase 3Diffuse Large B-Cell Lymphoma
Est. primary completion 2028-03 · NCT06508658 · CT.gov ↗
What to watch
VenetoclaxPhase 3Chronic Lymphocytic Leukemia
Est. primary completion 2028-03 · NCT06428019 · CT.gov ↗
What to watch
Atogepant (Qulipta)Phase 3Episodic Migraine
Est. primary completion 2028-03 · NCT05711394 · CT.gov ↗
What to watch
April 2028 (1)
risankizumab · SkyriziPhase 3Psoriasis
Est. primary completion 2028-04 · NCT04862286 · CT.gov ↗
What to watch
June 2028 (1)
Surabgene lomparvovecPhase 2/3Diabetic Retinopathy
Est. primary completion 2028-06 · NCT07592273 · CT.gov ↗
What to watch
July 2028 (3)
VenetoclaxPhase 2Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
Est. primary completion 2028-07 · NCT07387471 · CT.gov ↗
What to watch
RC148Phase 2Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy
Est. primary completion 2028-07 · NCT07895355 · CT.gov ↗
What to watch
VenetoclaxPhase 3Cancer
Est. primary completion 2028-07-05 · NCT03768063 · CT.gov ↗
What to watch
August 2028 (3)
upadacitinib · RinvoqPhase 3Takayasu Arteritis (TAK)
Est. primary completion 2028-08 · NCT04161898 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3Ulcerative Colitis
Est. primary completion 2028-08 · NCT05782907 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3Hidradenitis Suppurativa
Est. primary completion 2028-08 · NCT05889182 · CT.gov ↗
What to watch
September 2028 (2)
Telisotuzumab AdizutecanPhase 2Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
Est. primary completion 2028-09 · NCT07769502 · CT.gov ↗
What to watch
risankizumab · SkyriziPhase 3Ulcerative Colitis (UC)
Est. primary completion 2028-09 · NCT03398135 · CT.gov ↗
What to watch
December 2028 (3)
Surabgene lomparvovecPhase 2Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Est. primary completion 2028-12 · NCT03999801 · CT.gov ↗
What to watch
ABBV-295Phase 2Moderate to Severe Psoriasis
Est. primary completion 2028-12 · NCT07933536 · CT.gov ↗
What to watch
Telisotuzumab VedotinPhase 3Non Small Cell Lung Cancer, c-MET
Est. primary completion 2028-12 · NCT04928846 · CT.gov ↗
What to watch
2029 (19)
January 2029 (2)
EpcoritamabPhase 1/2DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL) …
Est. primary completion 2029-01 · NCT03625037 · CT.gov ↗
What to watch
Est. primary completion 2029-01 · NCT07059845 · CT.gov ↗
What to watch
February 2029 (3)
risankizumab · SkyriziPhase 3Crohn's Disease
Est. primary completion 2029-02 · NCT03105102 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3Alopecia Areata
Est. primary completion 2029-02 · NCT07023302 · CT.gov ↗
What to watch
VenetoclaxPhase 2Acute Myeloid Leukemia (AML)
Est. primary completion 2029-02-01 · NCT07423104 · CT.gov ↗
What to watch
April 2029 (3)
AGN-193408Phase 1/2Open-angle Glaucoma, Ocular Hypertension
Est. primary completion 2029-04 · NCT04499248 · CT.gov ↗
What to watch
ABBV-706Phase 2Small Cell Lung Cancer
Est. primary completion 2029-04 · NCT07155174 · CT.gov ↗
What to watch
risankizumab · SkyriziPhase 3Crohn's Disease
Est. primary completion 2029-04 · NCT05995353 · CT.gov ↗
What to watch
May 2029 (1)
Telisotuzumab AdizutecanPhase 3Colorectal Cancer
Est. primary completion 2029-05 · NCT07525206 · CT.gov ↗
What to watch
June 2029 (1)
upadacitinib · RinvoqPhase 3Juvenile Idiopathic Arthritis
Est. primary completion 2029-06 · NCT05609630 · CT.gov ↗
What to watch
July 2029 (1)
ABBV-722Phase 2Rheumatoid Arthritis
Est. primary completion 2029-07 · NCT07904754 · CT.gov ↗
What to watch
August 2029 (1)
risankizumab · Skyrizi + lutikizumab + ABBV-547Phase 2Psoriatic Arthritis
Est. primary completion 2029-08 · NCT06865105 · CT.gov ↗
What to watch
October 2029 (2)
ABBV-6628Phase 1/2Geographic Atrophy, Age-Related Macular Degeneration
Est. primary completion 2029-10 · NCT07160179 · CT.gov ↗
What to watch
Telisotuzumab AdizutecanPhase 2Head and Neck Squamous Cell Carcinoma
Est. primary completion 2029-10 · NCT07744126 · CT.gov ↗
What to watch
November 2029 (2)
Telisotuzumab AdizutecanPhase 2Colorectal Cancer
Est. primary completion 2029-11 · NCT07023289 · CT.gov ↗
What to watch
upadacitinib · RinvoqPhase 3Atopic Dermatitis
Est. primary completion 2029-11 · NCT06461897 · CT.gov ↗
What to watch
December 2029 (3)
ZumilokibartPhase 2Atopic Dermatitis
Est. primary completion 2029-12 · NCT07003425 · CT.gov ↗
What to watch
EpcoritamabPhase 3Follicular Lymphoma (FL)
Est. primary completion 2029-12 · NCT05409066 · CT.gov ↗
What to watch
RC148Phase 3Non-Small Cell Lung Cancer
Est. primary completion 2029-12 · NCT07756645 · CT.gov ↗
What to watch
2030 (12)
January 2030 (1)
Est. primary completion 2030-01 · NCT06548542 · CT.gov ↗
What to watch
February 2030 (1)
Mirvetuximab soravtansine · ElaherePhase 2Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
Est. primary completion 2030-02 · NCT06890338 · CT.gov ↗
What to watch
March 2030 (1)
Telisotuzumab AdizutecanPhase 3Non-Squamous Non-Small Cell Lung Cancer
Est. primary completion 2030-03 · NCT07821684 · CT.gov ↗
What to watch
April 2030 (2)
upadacitinib · RinvoqPhase 3Alopecia Areata
Est. primary completion 2030-04 · NCT06012240 · CT.gov ↗
What to watch
RC148Phase 2/3Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2030-04-30 · NCT07935369 · CT.gov ↗
What to watch
September 2030 (2)
Telisotuzumab AdizutecanPhase 2/3Non-Small Cell Lung Cancer, c-MET
Est. primary completion 2030-09 · NCT07155187 · CT.gov ↗
What to watch
ABBV-706Phase 3Small Cell Lung Cancer
Est. primary completion 2030-09 · NCT07365241 · CT.gov ↗
What to watch
October 2030 (2)
ABBV-1758Phase 1/2Alzheimer's Disease
Est. primary completion 2030-10 · NCT07599670 · CT.gov ↗
What to watch
Budigalimab + Telisotuzumab AdizutecanPhase 2Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Est. primary completion 2030-10 · NCT06628310 · CT.gov ↗
What to watch
December 2030 (3)
Etentamig + SurzetoclaxPhase 1/2Multiple Myeloma
Est. primary completion 2030-12 · NCT06953960 · CT.gov ↗
What to watch
VenetoclaxPhase 2Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Est. primary completion 2030-12 · NCT02966756 · CT.gov ↗
What to watch
Telisotuzumab AdizutecanPhase 2Solid Tumors Harboring MET Amplification
Est. primary completion 2030-12 · NCT07196644 · CT.gov ↗
What to watch
2031 (9)
January 2031 (1)
upadacitinib · RinvoqPhase 3Crohn's Disease
Est. primary completion 2031-01 · NCT06332534 · CT.gov ↗
What to watch
March 2031 (1)
Atogepant (Qulipta)Phase 3Chronic Migraine
Est. primary completion 2031-03 · NCT06810505 · CT.gov ↗
What to watch
April 2031 (1)
RC148Phase 3Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations
Est. primary completion 2031-04 · NCT07829549 · CT.gov ↗
What to watch
May 2031 (1)
VenetoclaxPhase 2Multiple Myeloma
Est. primary completion 2031-05 · NCT03314181 · CT.gov ↗
What to watch
June 2031 (1)
Telisotuzumab AdizutecanPhase 2/3Metastatic Pancreatic Ductal Adenocarcinoma, PDAC
Est. primary completion 2031-06 · NCT07490301 · CT.gov ↗
What to watch
August 2031 (1)
ABBV-706Phase 2Extensive Stage-Small Cell Lung Cancer
Est. primary completion 2031-08 · NCT07895056 · CT.gov ↗
What to watch
October 2031 (2)
risankizumab · Skyrizi + TrosunilimabPhase 2Crohn's Disease, Ulcerative Colitis
Est. primary completion 2031-10 · NCT07697456 · CT.gov ↗
What to watch
BudigalimabPhase 2/3Non-Small Cell Lung Cancer
Est. primary completion 2031-10 · NCT06236438 · CT.gov ↗
What to watch
December 2031 (1)
ABBV-706Phase 2Extensive Stage-Small Cell Lung Cancer (ES-SCLC)
Est. primary completion 2031-12 · NCT07895043 · CT.gov ↗
What to watch
2032 (5)
March 2032 (1)
upadacitinib · RinvoqPhase 3Severe Alopecia Areata
Est. primary completion 2032-03 · NCT07772492 · CT.gov ↗
What to watch
April 2032 (1)
Atogepant (Qulipta)Phase 3Migraine Prophylaxis
Est. primary completion 2032-04 · NCT05707949 · CT.gov ↗
What to watch
June 2032 (1)
Venetoclax + Pivekimab Sunirine · DecnupazPhase 2/3Acute Myeloid Leukemia
Est. primary completion 2032-06 · NCT07581002 · CT.gov ↗
What to watch
August 2032 (1)
upadacitinib · RinvoqPhase 3Non-Segmental Vitiligo
Est. primary completion 2032-08 · NCT07896434 · CT.gov ↗
What to watch
November 2032 (1)
EpcoritamabPhase 2Non-Hodgkin Lymphoma
Est. primary completion 2032-11 · NCT05283720 · CT.gov ↗
What to watch
2033 (2)
February 2033 (1)
EtentamigPhase 3Relapsed or Refractory Multiple Myeloma
Est. primary completion 2033-02 · NCT07728188 · CT.gov ↗
What to watch
March 2033 (1)
Surabgene lomparvovecPhase 3Neovascular Age-related Macular Degeneration
Est. primary completion 2033-03 · NCT07007065 · CT.gov ↗
What to watch
2034 (2)
July 2034 (1)
risankizumab · SkyriziPhase 3Ulcerative Colitis
Est. primary completion 2034-07 · NCT07071519 · CT.gov ↗
What to watch
December 2034 (1)
EtentamigPhase 3Amyloid Light Chain (AL) Amyloidosis
Est. primary completion 2034-12 · NCT07793422 · CT.gov ↗
What to watch
2035 (2)
June 2035 (1)
upadacitinib · Rinvoq + ABBV-722Phase 2/3Systemic Sclerosis
Est. primary completion 2035-06 · NCT07933211 · CT.gov ↗
What to watch
December 2035 (1)
Etentamig + ABBV-2001Phase 1/2Multiple Myeloma
Est. primary completion 2035-12 · NCT06892522 · CT.gov ↗
What to watch
2036 (1)
November 2036 (1)
Telisotuzumab AdizutecanPhase 2/3Non-Squamous Non-Small Cell Lung Cancer, c-MET
Est. primary completion 2036-11 · NCT07005102 · CT.gov ↗
What to watch
2037 (1)
November 2037 (1)
EpcoritamabPhase 3Follicular Lymphoma (FL)
Est. primary completion 2037-11 · NCT06191744 · CT.gov ↗
What to watch
2041 (1)
March 2041 (1)
EtentamigPhase 2/3Multiple Myeloma
Est. primary completion 2041-03 · NCT07095452 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(39)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 October 2026Filing submittedEtentamigAbbVie submits a BLA for etentamig in relapsed or refractory multiple myeloma
US, FDA · Source ↗
23 October 2026ApprovalrisankizumabFDA approves SC induction regimen for Skyrizi in Crohn's disease
US, FDA · Source ↗
22 October 2026Topline resultlutikizumabPhase 3 INTREPID (NCT06468228) of lutikizumab in hidradenitis suppurativa met its HiSCR75 primary endpoint
October 2026Topline resultEpcoritamabPhase 3 EPCORE DLBCL-2 positive topline results
30 September 2026Topline resultZumilokibartPhase 2 APEX Part B primary results
22 September 2026ApprovalupadacitinibEuropean Commission approves Rinvoq for polyarticular juvenile idiopathic arthritis
EU, EC · AbbVie · Source ↗
10 September 2026Topline resultAtogepant (Qulipta)LUNA Phase 3 in menstrual migraine meets its primary endpoint
AbbVie · Source ↗
3 September 2026Topline resultEtentamigPhase 3 CERVINO meets both primary endpoints (ORR and PFS)
AbbVie · Source ↗
September 2026ApprovalTavapadonFDA approves Juvmo for Parkinson's disease
US, FDA · AbbVie · Source ↗
29 July 2026ApprovalupadacitinibEuropean Commission approves Rinvoq in severe alopecia areata
EU, EC · Source ↗
July 2026ApprovalEpcoritamabEuropean Commission approves Tepkinly with lenalidomide and rituximab in R/R follicular lymphoma
EU, European Commission · Source ↗
June 2026Topline resultEpcoritamabPhase 3 EPCORE DLBCL-4 met its progression-free survival primary endpoint

The 12 most recent of 39 past events are shown.

Financial reports

Quarterly & interim (21)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$17.4B$2.6B$10.8B—$7.6B operating cash flowreport ↗
View 20 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$17.0B$2.3B$6.6B—$3.4B operating cash flowreport ↗
2026-Q1$15.0B$2.5B$9.4B—$3.8B operating cash flowreport ↗
2025-Q4$16.6B$2.6B$5.3B+ $28M short-term inv.—$5.2B operating cash flowreport ↗
2025-Q3$15.8B$2.3B$5.7B+ $42M short-term inv.—$7.0B operating cash flowreport ↗
2025-Q2$15.4B$2.1B$6.5B+ $0 short-term inv.—$5.2B operating cash flowreport ↗
2025-Q1$13.3B$2.1B$5.2B+ $1.0M short-term inv.—$1.6B operating cash flowreport ↗
2024-Q4$15.1B$6.8B$5.6B+ $31M short-term inv.—$7.0B operating cash flowreport ↗
2024-Q3$14.5B$2.1B$7.3B+ $28M short-term inv.—$5.4B operating cash flowreport ↗
2024-Q2$14.5B$1.9B$13.2B+ $27M short-term inv.—$2.3B operating cash flowreport ↗
2024-Q1$12.3B$1.9B$18.1B+ $2.0M short-term inv.—$4.0B operating cash flowreport ↗
2023-Q4$14.3B—$12.8B+ $2.0M short-term inv.—$4.8B operating cash flowreport ↗
2023-Q3$13.9B$1.7B$13.3B+ $3.0M short-term inv.—$7.6B operating cash flowreport ↗
2023-Q2$13.9B$1.7B$8.8B+ $7.0M short-term inv.—$6.3B operating cash flowreport ↗
2023-Q1$12.2B$2.3B$6.7B+ $11M short-term inv.—$4.2B operating cash flowreport ↗
2022-Q4$15.1B—$9.2B+ $28M short-term inv.—$7.4B operating cash flowreport ↗
2022-Q3$14.8B$1.6B$11.8B+ $47M short-term inv.—$7.6B operating cash flowreport ↗
2022-Q2$14.6B$1.6B$8.5B+ $1.4B short-term inv.—$5.0B operating cash flowreport ↗
2022-Q1$13.5B$1.5B$6.1B+ $1.5B short-term inv.—$4.9B operating cash flowreport ↗
2021-Q4$14.9B—$9.7B+ $84M short-term inv.—$5.1B operating cash flowreport ↗
2021-Q3$14.3B$1.7B$12.2B+ $67M short-term inv.—$7.9B operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$61.2B$9.1B$5.3B+ $28M short-term inv.—$19.0B operating cash flowreport ↗

AbbVie reported FY2025 revenue of $61,160M, up 305.0% YoY. R&D spend was $9,096M, up 34.3% YoY. Cash and equivalents stood at $5,257M, and the company recorded net income of $4,226M.

The company outlined 2026 strategic objectives including advancing late-stage pipeline milestones and expecting several regulatory submissions, approvals, and clinical data readouts over the next 12 months. Key developments included Rinvoq approvals for giant cell arteritis and positive Phase 3 results in alopecia areata and vitiligo, accelerated FDA approval of Emrelis, FDA approval of Epkinly for relapsed/refractory follicular lymphoma, and regulatory submissions for tavapadon, PVEK, and TrenibotE. The Venclexta VERONA trial missed its primary endpoint. AbbVie also announced a voluntary U.S. government agreement pledging $100 billion in U.S. R&D and capital investment, a CEO/board chairman transition effective July 2025, and Rinvoq patent settlements expected to prevent generic entry before April 2037.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$56.3B$12.8B$5.6B+ $31M short-term inv.—$18.8B operating cash flowreport ↗
2023-FY$54.3B$7.7B$12.8B+ $2.0M short-term inv.—$22.8B operating cash flowreport ↗
2022-FY$58.1B$6.5B$9.2B+ $28M short-term inv.—$24.9B operating cash flowreport ↗
2021-FY$56.2B$7.1B$9.7B+ $84M short-term inv.—$22.8B operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 7 sales ($30.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16SALEKI AZITA · EVP, CHIEF OPERATIONS OFFICEROption exercise23,935$61.36$1.5MForm 4
2026-11-16SALEKI AZITA · EVP, CHIEF OPERATIONS OFFICERTax withholding13,481$298.55$4.0MForm 4
2026-11-16SALEKI AZITA · EVP, CHIEF OPERATIONS OFFICEROption exercise (derivative)13,481——Form 4
2026-11-12Stewart Jeffrey Ryan · EVP, CHIEF COMMERCIAL OFFICERGift3,450——Form 4
2026-11-09Stewart Jeffrey Ryan · EVP, CHIEF COMMERCIAL OFFICEROption exercise16,070$114.36$1.8MForm 4
2026-11-09Stewart Jeffrey Ryan · EVP, CHIEF COMMERCIAL OFFICEROption exercise24,549$93.50$2.3MForm 4
2026-11-09Stewart Jeffrey Ryan · EVP, CHIEF COMMERCIAL OFFICEROpen-market sale40,619$293.60$11.9MForm 4
2026-11-09Stewart Jeffrey Ryan · EVP, CHIEF COMMERCIAL OFFICEROption exercise (derivative)16,070——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 3,998 reporting institutions held 1294.7M shares ($271.3B, 73.2% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.150,698,125$32.8B
2VANGUARD CAPITAL MANAGEMENT LLC114,880,324$25.0B
3STATE STREET CORP81,217,516$17.7B
4JPMORGAN CHASE & CO56,741,691$12.1B
5VANGUARD PORTFOLIO MANAGEMENT LLC49,523,078$10.8B
6GEODE CAPITAL MANAGEMENT, LLC46,737,581$10.1B
7MORGAN STANLEY38,016,774$8.3B
8Capital Research Global Investors31,254,786$6.8B
9BANK OF AMERICA CORP /DE/23,936,943$5.2B
10FMR LLC21,762,703$4.7B
11NORTHERN TRUST CORP21,211,382$4.6B
12Capital World Investors15,841,367$3.4B
13GOLDMAN SACHS GROUP INC15,145,279$3.3B
14FRANKLIN RESOURCES INC14,552,069$3.2B
15Capital International Investors14,418,993$3.1B